Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Published:2021-02 Issue:2 Volume:21 Page:213-225
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Wunderink Richard G,Matsunaga Yuko,Ariyasu Mari,Clevenbergh Philippe,Echols Roger,Kaye Keith S,Kollef Marin,Menon Anju,Pogue Jason M,Shorr Andrew F,Timsit Jean-Francois,Zeitlinger Markus,Nagata Tsutae D

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference30 articles.

1. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia;Torres;ERJ Open Res,2018

2. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria;Cillóniz;Curr Opin Infect Dis,2019

3. Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?;Bassetti;Crit Care,2016

4. Nosocomial Acinetobacter pneumonia: treatment and prognostic factors in 356 cases;Özvatan;Respirology,2016

5. Rationalizing antimicrobial therapy in the ICU: a narrative review;Timsit;Intensive Care Med,2019

Cited by 293 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis;BMC Infectious Diseases;2024-09-13

2. Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study;Pediatric Infectious Disease Journal;2024-09-04

3. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria;International Journal of Antimicrobial Agents;2024-09

4. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

5. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria;Communications Medicine;2024-08-29